Lexaria Bioscience (LEXX) Net Cash Flow Growth (1y) (2011 - 2026)
Lexaria Bioscience (LEXX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Lexaria Bioscience |
7.49 Mn |
1.97 Mn |
20,000.00 |
154.57% |
| Date | Value |
|---|
| Feb 28, 2026 |
154.57% |
| Nov 30, 2025 |
57.12% |
| Aug 31, 2025 |
-42.79% |
| May 31, 2025 |
-150.98% |
| Feb 28, 2025 |
-154.54% |
| Nov 30, 2024 |
164.61% |
| Aug 31, 2024 |
-8.25% |
| May 31, 2024 |
3,570.48% |
| Feb 29, 2024 |
320.17% |
| Nov 30, 2023 |
146.69% |
| Aug 31, 2023 |
-46.37% |
| May 31, 2023 |
91.73% |
| Feb 28, 2023 |
4.68% |
| Nov 30, 2022 |
-3.61% |
| Aug 31, 2022 |
-142.80% |
| May 31, 2022 |
-5.64% |
| Feb 28, 2022 |
-115.04% |
| Nov 30, 2021 |
-49.93% |
| Aug 31, 2021 |
489.72% |
| May 31, 2021 |
-200.00% |
